The Vonoprazan Fumarate API market is rapidly expanding, driven by growing global prevalence of acid-related gastrointestinal disorders and increasing preference for more effective therapies. Vonoprazan, a potassium-competitive acid blocker (P-CAB), is often seen as an improvement over conventional proton pump inhibitors (PPIs) because of its faster onset of action and stronger acid...
Bangla